

Journal of Medical Microbiology

Curing vector for IncI1 plasmids and its use to provide evidence for a metabolic burden of IncI1 CTX-M-1 plasmid pIFM3791 on *Klebsiella pneumoniae* --Manuscript Draft--

Manuscript Number:	JMM-D-15-00870R1
Full Title:	Curing vector for IncI1 plasmids and its use to provide evidence for a metabolic burden of IncI1 CTX-M-1 plasmid pIFM3791 on <i>Klebsiella pneumoniae</i>
Short Title:	CTX-M-1 plasmid pIFM3791 imposes a phenotypic burden upon <i>Klebsiella pneumoniae</i>
Article Type:	Standard
Section/Category:	Clinical Microbiology
Corresponding Author:	Irene Freire Martín Animal and Plant Health Agency UNITED KINGDOM
First Author:	Irene Freire Martín
Order of Authors:	Irene Freire Martín Christopher M. Thomas Emma Laing Manal AbuOun Roberto M. La Ragione Martin J. Woodward
Abstract:	<p>Using a sequence based approach we previously identified an IncI1 CTX-M-1 plasmid, pIFM3791, on a single pig farm in the UK that was harboured by <i>K. pneumoniae</i>, <i>Escherichia coli</i> and <i>Salmonella enterica</i> serotype 4,5,12,i:-. To test the hypothesis that the plasmid had spread rapidly into these differing host bacteria we wished to assess whether the plasmid conferred a fitness advantage. To do this an IncI1 curing vector was constructed and used to displace the IncI1 CTX-M-1 plasmids from <i>K. pneumoniae</i> strain B3791 and several other unrelated IncI1 harbouring strains indicating the potential wider application of the curing plasmid. The IncI1 CTX-M-1 plasmid was re-introduced by conjugation into the cured <i>K. pneumoniae</i> strain and also a naturally IncI1 plasmid free <i>S. enterica</i> serotype 4,5,12,i:-, S348/1. Original, cured and complemented strains were tested for metabolic competence using Biolog™ technology and in competitive growth, association to mammalian cells and biofilm formation experiments. The plasmid-cured <i>K. pneumoniae</i> strain grew more rapidly than either the original plasmid-carrying strain or plasmid-complemented strains in competition experiments. Additionally, the plasmid-cured strain was significantly better at respiring with L-sorbose as a carbon source and putrescine, γ-amino-n-butyric acid, L-alanine, L-proline as a nitrogen sources. By contrast, no differences in phenotype were found when comparing plasmid harbouring and plasmid free <i>S. enterica</i> S348/1. In conclusion, the IncI1 curing vector successfully displaced multiple IncI plasmids. The IncI1 CTX-M1 plasmid conferred a growth disadvantage upon <i>K. pneumoniae</i>, possibly by imposing a metabolic burden the mechanism of which remains to be determined.</p>

1 **Curing vector for IncI1 plasmids and its use to provide evidence for a**
2 **metabolic burden of IncI1 CTX-M-1 plasmid pIFM3791 on *Klebsiella***
3 ***pneumoniae***

4 Irene Freire Martín^{1*}, Christopher M. Thomas², Emma Laing³, Manal AbuOun¹,
5 Roberto M. La Ragione^{1,4}, Martin J. Woodward⁵.

6 ¹ APHA, Woodham Lane, New Haw, Addlestone Surrey, KT15 3NB, UK.

7 ² School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT,
8 UK.

9 ³ School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey,
10 Guildford, Surrey, UK, GU2 7XH

11 ⁴ School of Veterinary Medicine, Faculty of Health and Medical Sciences, University of
12 Surrey, Guildford, Surrey, UK, GU2 7AL

13 ⁵Department of Food and Nutritional Sciences, University of Reading, Whiteknights
14 Park, Reading RG6 5AP, UK.

15 ***Corresponding author contact details:**

16 Email: Irene.Freire-Martin@phe.gov.uk; Telephone: +441980612347 Fax:
17 +4401980611316 Current Address: Pathogen Immunology Programme, Public Health
18 England, Microbiology Services Division, Porton Down, Salisbury, SP4 0JG

19 **Keywords:** IncI1 curing vector, ESBL, Veterinary microbiology, Enterobacteriaceae

20 **Running Title:** CTX-M-1 plasmid pIFM3791 imposes a phenotypic burden upon
21 *Klebsiella pneumoniae*

22 **Abstract word count:** 281

23 **Main body word count:** 3632

24 **Subject category:** Antimicrobial agents and chemotherapy

25 **Abstract**

26 Using a sequence based approach we previously identified an IncII CTX-M-1 plasmid,
27 pIFM3791, on a single pig farm in the UK that was harboured by *K. pneumoniae*,
28 *Escherichia coli* and *Salmonella enterica* serotype 4,5,12,i:-. To test the hypothesis that
29 the plasmid had spread rapidly into these differing host bacteria we wished to assess
30 whether the plasmid conferred a fitness advantage. To do this an IncII curing vector
31 was constructed and used to displace the IncII CTX-M-1 plasmids from *K. pneumoniae*
32 strain B3791 and several other unrelated IncII harbouring strains indicating the
33 potential wider application of the curing plasmid. The IncII CTX-M-1 plasmid was re-
34 introduced by conjugation into the cured *K. pneumoniae* strain and also a naturally
35 IncII plasmid free *S. enterica* serotype 4,5,12,i:-, S348/1. Original, cured and
36 complemented strains were tested for metabolic competence using Biolog™ technology
37 and in competitive growth, association to mammalian cells and biofilm formation
38 experiments. The plasmid-cured *K. pneumoniae* strain grew more rapidly than either the
39 original plasmid-carrying strain or plasmid-complemented strains in competition
40 experiments. Additionally, the plasmid-cured strain was significantly better at respiring
41 with L-sorbose as a carbon source and putrescine, γ -amino-n-butyric acid, L-alanine, L-
42 proline as a nitrogen sources. By contrast, no differences in phenotype were found when
43 comparing plasmid harbouring and plasmid free *S. enterica* S348/11. In conclusion, the
44 IncII curing vector successfully displaced multiple IncI plasmids. The IncII CTX-M1
45 plasmid conferred a growth disadvantage upon *K. pneumoniae*, possibly by imposing a
46 metabolic burden the mechanism of which remains to be determined.

47 **Introduction**

48 Extended Spectrum β -Lactamases (ESBL) confer resistance to most penicillins and
49 monobactams and, more significantly, the clinically important cephalosporins
50 (Gniadkowski, 2001). The CTX-M class of ESBLs has become the most prevalent type
51 isolated from clinical settings (Livermore *et al.*, 2007), and is increasingly common in
52 community and veterinary isolates (Batchelor *et al.*, 2005; Pitout *et al.*, 2005).
53 Awareness of the potential spread of this resistance in livestock has increased (Horton *et*
54 *al.*, 2011). Furthermore, recent genome sequencing data of human and food animal
55 *Escherichia coli* isolates from the Netherlands indicate that the dissemination of
56 resistance across reservoirs is caused by the expansion of successful plasmid lineages
57 (de Been *et al.*, 2014).

58 During a diagnostic investigation in 2009 into pig mortality related to diarrhoea
59 on a single pig farm in the UK, CTX-M-1 harbouring *Klebsiella pneumoniae*,
60 *Escherichia coli* and *Salmonella* of serotypes 4,5,12,i:- and Bovismorbificans were
61 recovered. Genotyping methods suggested the dissemination of a common IncII-CTX-
62 M-1 plasmid, which was demonstrated by sequencing a plasmid isolated from each of
63 the bacterial species present in the farm. These plasmids, pIFM3791, pIFM3804 and
64 pIFM3844 had been found to be identical, excepting a small number (n=7) of mutations
65 (see supplementary data for Table S1) (Freire Martín *et al.*, 2014). These findings
66 prompted the question whether or not this plasmid conferred a fitness advantage to the
67 host bacterium, possibly beyond the resistance phenotype. Plasmids may confer a
68 selective advantage to their host even in the absence of antibiotic selective pressure as
69 suggested by Enne *et al.* (2004). The plasmids present in this farm may themselves
70 confer a selective advantage, especially as there was no recent evidence of use of lactam
71 based antibiotics on this farm. To assess this, our aim was to prepare plasmid bearing

72 and plasmid free isogenic strains for phenotypic testing and two approaches were used.
73 One was to place the plasmids of interest in a common isogenic background. The other
74 was to generate cured host strains for which a number of methods have been described.
75 Commonly used methods include continuous non-selective passage or growth in the
76 presence of sub-lethal concentrations of DNA intercalating agents, but both methods
77 may accumulate mutations (Ferguson & Denny, 2007). Thus, for this study we opted for
78 the use of incompatibility based curing following the observation that two plasmids
79 bearing the same replicon cannot be stably maintained in a bacterium (Couturier *et al.*,
80 1988). Plasmid incompatibility based curing has been successfully employed for curing
81 of plasmids (Hale *et al.*, 2010; Tatsuno *et al.*, 2001), but not as yet for IncI1 plasmids.
82 Here we describe the construction of a curing tool for IncI1 CTX-M plasmids and then
83 the phenotypic analyses of plasmid free and plasmid carrying strains.

84

85 **Materials and methods**

86 **Bacterial strains and plasmids**

87 The strains and plasmids described in this study were either wild-type and originating
88 from previous studies (Freire Martín *et al.*, 2014; Horton *et al.*, 2011; Randall *et al.*,
89 2012), commercially available strains and plasmids, or, in the case of pIFM26 (S1), a
90 modification of previously described plasmid pAKE604 (El-Sayed *et al.*, 2001), which
91 differed from it only in the orientation of the restriction sites within its MCS. The
92 strains were grown in LB medium and, when necessary for plasmid maintenance, in the
93 presence of appropriate antibiotics.

94 **Generation of curing vector pIFM27**

95 Exponentially growing bacteria were made electrocompetent through successive water
96 and glycerol washes. For molecular cloning, amplified PCR products were digested

97 using commercially available enzymes and ligated to digested vectors using standard
98 techniques, a description of which has been included within the supplementary
99 materials (S1). The final curing vector was named pIFM27 and it harboured negative
100 selection gene *sacB*, resistance markers *kan^r*, *amp^r* and *aac6-Ib* and IncI1 plasmid
101 replication down-regulator *RNAI* alongside its native promoter (Fig. 1).

102 **Plasmid conjugation**

103 Stationary, antibiotic free LB broth cultures of donor (50µl) and recipient (150µl) were
104 mixed and overlaid on a polycarbonate 0.2µm filter placed on the centre of a LB agar
105 plate and incubated at 37°C for 24hrs. The bacteria were washed with 2ml of PBS and
106 transconjugants selected by plating on Rambach agar plates supplemented with 10µg/ml
107 of tetracycline and 2µg/ml of cefotaxime. Tetracycline was chosen as the intended
108 recipients had been shown to be resistant during extensive characterisation carried out
109 as part of previous work (Freire Martín *et al.*, 2014). Colonies of the appropriate colour
110 (red for the *S. enterica* strains, purple for the *K. pneumoniae* strains) were re-streaked
111 and checked for the presence of the incoming plasmid by CTX-M universal PCR and
112 plasmid profiling.

113 **Characterization methods used for verification of curing, conjugation and strain** 114 **identity**

115 Macro-restriction profiles of strains were obtained by *XbaI* Pulsed Field Gel
116 Electrophoresis (PFGE) as described by the PulseNet network (Gerner-Smidt *et al.*,
117 2006). Electrophoresis conditions were 14°C at 6V/cm for 19.5h with switch times
118 ranging from 2.2 to 54.2s of linear ramping for the *K. pneumoniae* strains and 2.2 to
119 63.8s for the *S. enterica* strains. Gel images were analysed using of BioNumerics
120 software (v.6.6; Applied Maths, Belgium).

121 Plasmid profiling was performed following the method of Kado and Liu (1981). As
122 reference supercoiled DNA ladder (Sigma-Aldrich D5292), reference strain 39R861 and
123 reference strain 20R764 were also run.

124 A number of primers were also used to test for the presence of certain genes within the
125 strains throughout the different stages of curing using PCR, as described in the results.

126 See Table 1 for the primer sequences. The PCR ramping conditions were in every case
127 25 cycles of 94°C for 30s, 60°C for 30s and 72°C for 1m.

128 **Phenotypic tests of plasmid burden by Biolog Phenotype Microarray**

129 Biolog™ plates PM2 and PM3 were used following manufacturer's instructions.
130 Biolog™ output data files were imported into R (<http://www.R-project.org>; R Core
131 Team, R: A Language and Environment for Statistical Computing, R Foundation for
132 Statistical Computing, Vienna, Austria, 2014) and the kinetic curves for each biological
133 replicate were fitted using the Grofit package (Kahm *et al.*, 2010). The features studied
134 were: the area under the curve (AUC), the maximum value achieved (MaxV), and the
135 fastest rate of increase (RateI).

136 **Competitive growth curves**

137 Competition experiments of plasmid-free vs. plasmid-harboursing strains were set up and
138 carried out as previously described (Lenski *et al.*, 1994). A sample of the competition
139 mixture at time 0, and thereafter every 24hrs for 6 days, was serially diluted and plated
140 on LB agar and LB agar supplemented with 2µg/ml of cefotaxime to obtain counts of
141 total bacteria and of resistant bacteria, respectively. To calculate the selection rate the
142 natural log of the ratio of plasmid-bearing/plasmid-free for each day was plotted for
143 each competition. The selection rate was taken as the slope of the equation defining the
144 line of best fit. Each competition was repeated four times and two tailed t-tests were

145 carried out to determine whether the mean selection rate for each pair of strains
146 competed was significantly different from 0.

147 **Association of *K. pneumoniae* to cultured monolayers of mammalian cells**

148 The porcine intestinal epithelial cell line IPEC-J2 was used. Specifically, 2 day old cells
149 cultured to confluency in 24 well plates were used. On the day of the assay, the culture
150 medium was removed from the wells and the cells were washed twice with Hank's
151 balanced salts solution to remove residual antibiotics. The bacterial inocula were
152 resuspended in Ham's F12/DMEM supplemented with 2% mannose and delivered in
153 volumes of 1ml at a density of $\sim 10^7$ CFU/ml per well in triplicate. The plates were then
154 incubated for 1hr in an atmosphere of 5% CO₂ at 37°C with 100% humidity. After
155 incubation, the bacterial inocula were removed and the wells washed three times with
156 HBSS. After washing, the cells were disrupted by addition of 1% Triton-X 100 (in PBS)
157 with mechanical stirring followed by serial dilution and plating on LB agar (Favre-
158 Bonte *et al.*, 1999).

159 **Association and invasion of *S. enterica* to cultured monolayers of mammalian cells**

160 Association of *S. enterica* was evaluated in the same manner as above with minor
161 differences. Specifically, the bacterial inocula were delivered as 1ml of $\sim 3.5 \times 10^7$
162 CFU/ml suspended in Ham's F12/DMEM with a co-incubation step of 2hr. A second
163 plate was set up identically and used for the enumeration of intracellular bacteria
164 (invasion). After co-incubation and washing, the monolayers were overlaid with
165 Ham's F12/DMEM supplemented with 150mg/L colistin and incubated for 90min. The
166 antibiotic containing medium was removed and the wells were washed three times with
167 HBSS. After washing, the cells were disrupted and the bacteria were enumerated as
168 described above (Searle *et al.*, 2009).

169 **Biofilm formation**

170 Stationary bacteria were seeded at 0.05_{OD570} and cultured statically in LB (*K.*
171 *pneumoniae*) or LB without salt (*S. enterica*) within triplicate wells in microplates for
172 24h at 25°C and 37°C. The culture was discarded, the wells were washed 3 times with
173 PBS and 130µl of 1% crystal violet was added to the wells and incubated at room
174 temperature for 30 min. The crystal violet solution was then discarded and the wells
175 were washed 4 times with distilled water. To solubilise the bound crystal violet, 130µl
176 of ethanol/acetone (70/30 v/v) was added to the wells and after 10min the _{OD570}
177 determined (Woodward *et al.*, 2000). The experiments were carried out three times for
178 each strain and temperature.

179 **Statistical analysis of phenotypic assays**

180 For each of the measured phenotypes statistical analysis to compare strains was
181 performed using the triplicate measurements for each strain as input to a one way
182 ANOVA test. Any ANOVA test having a P-value <0.05, indicating that there is a
183 difference in feature values between at least two strains, was followed by a Tukey's
184 HSD post-hoc test, where a P-value < 0.05 for a specific strain comparison denoted a
185 significant difference. For the Biolog experiment this analysis was carried out in R
186 whereas for the remaining experiments statistical analysis was carried out using
187 GraphPad Prism 5.

188

189 **Results**

190 **Construction of the IncI1 curing plasmid: selection of targets and vector**

191 The DNA sequences of IncI1-CTX-M-1 plasmids from *K. pneumoniae*, *E. coli* and *S.*
192 *enterica* 4,5,12;i;- identified during a pig farm investigation (Freire Martín *et al.*, 2014)
193 were analysed. The aim of this analysis was to identify genes involved in replication
194 and maintenance in order to target them with the curing vector. A single replicon was

195 identified as well as addiction system *pndA/C*. In the first instance, the RNA gene,
196 *RNAI*, which controls the copy number in IncI1 plasmids by translational regulation of
197 replication initiator *repZ* (Praszkier & Pittard, 2005), was amplified by PCR and cloned
198 into suicide vector pIFM26 (see supplementary material). This vector is not stable in the
199 absence of selection which, together with the presence of negative selection marker
200 *sacB* (confers sucrose sensitivity to Gram negative organisms), would enable recovery
201 of vector free clones by growth on antibiotic-free sucrose-containing media (Hale *et al.*,
202 2010).

203 *K. pneumoniae* strain B3791 is naturally resistant to both kanamycin and
204 ampicillin, the markers present in pIFM26. An alternative selectable marker was
205 required and so an amikacin resistance determinant *aac6-Ib* was cloned from plasmid
206 CB01 and inserted to create pIFM27 (pIFM26::*RNAI*::*aac6-Ib*) (Fig. 1). CB01 was a
207 wild type plasmid isolated by C. Boinet (unpublished thesis).

208 **Curing *K. pneumoniae* strain B3791 of IncI1 CTX-M plasmid by transformation** 209 **with pIFM27**

210 To validate the use of curing vector pIFM27 curing tests were performed with
211 wild type strains carrying IncI1-CTX-M-1 plasmids from sources other than the farm
212 pertaining to this study. LREC215, a commensal *E. coli* isolated from a broiler chick
213 (Horton *et al.*, 2011) and LREC447, an avian pathogenic *E. coli* isolated from a broiler
214 (Randall *et al.*, 2012), were confirmed by PCR to carry a CTX-M group 1 gene on an
215 IncI1- γ plasmid and to be sensitive to kanamycin, a strong selectable marker present in
216 pIFM27. Electrocompetent cells were transformed with curing vector pIFM27 with
217 selection on kanamycin (50mg/L). Four colonies from each transformation were tested
218 for the acquisition of pIFM27 by vector PCR. 100% of the colonies tested were shown
219 to be sensitive to cefotaxime and no longer carried their respective CTX-M plasmids as

220 shown by both CTX-M PCR and plasmid profiling. pIFM27 was excluded from the
221 transformants by culture in LB followed by recovery on LB agar supplemented with 5%
222 sucrose. Eight colonies recovered on sucrose supplemented agar for each strain were
223 tested by vector PCR and plasmid profiling which showed that the vector had been
224 successfully excluded. As the presence of *RNAI* in this vector was sufficient for the
225 exclusion of the target plasmid there was no need to pursue the making of a pndA/C
226 harbouring construct.

227 In the case of *K. pneumoniae* B3791 curing vector pIFM27 was electroporated
228 with selection on amikacin 2mg/L. This resulted in forty putative transformant colonies
229 of which three had acquired pIFM27, as confirmed by vector PCR. The remainder were
230 most likely spontaneous resistant mutants which is possible given the recipient strain
231 harboured another aminoglycoside resistance gene, a family of compounds against
232 which cross-resistance is known to occur (Shaw *et al.*, 1993). The three genuine
233 transformants were sensitive to cefotaxime (2mg/L) and had lost pIFM3791, as verified
234 by CTX-M PCR and plasmid profiling. pIFM27 was excluded from these three by
235 culture on LB agar supplemented with 5% sucrose. Six randomly selected sucrose
236 resistance derivatives from each transformant were negative for pIFM27 by PCR, their
237 *XbaI* PFGE banding patterns were all highly similar if not identical to that of B3791 and
238 plasmid profiles showed loss of a ~8kb plasmid, namely pIFM27. The remaining native
239 plasmids present in B3791 remained unaffected throughout the curing process (Fig. 2).
240 Collectively, these data indicated that curing vector pIFM27 excluded the IncII plasmid
241 from strain B3791. One cured derivative, designated CL32, was taken forward for
242 further analysis. The curing of an *E. coli* and a *Salmonella* 4,5,12,i:- originally isolated
243 from the same farm as *K. pneumoniae* B3791 (Freire Martín *et al.*, 2014) was also
244 attempted. This was, however, unsuccessful due to high levels of resistance to multiple

245 antibiotic and we did not investigate other selectable markers in this proof of concept
246 study.

247

248 **Re-introduction of the IncI1 CTX-M1 plasmids into cured *K. pneumoniae*, strain** 249 **CL32.**

250 Having prepared CL32, the plasmid cured derivative of *K. pneumoniae* B3791,
251 the last step in constructing strains for plasmid phenotype comparisons was to re-
252 introduce the outbreak plasmids into CL32. Solid surface mating conjugations were set
253 up with strains CL32 as recipient and laboratory strains of *E. coli* (NEB10iβ)
254 harbouring pIFM3791 (isolated from *K. pneumoniae*), pIFM3904 (isolated from *E. coli*)
255 and pIFM3844 (isolated from *Salmonella* 4,5,12:i:-), respectively, as donors. DNA
256 sequence analysis had previously shown these to plasmids to be very similar to each
257 other except for a small number of SNPs. As part of this work we wished to test whether
258 these differences represented adaptations to the harbouring species (Freire Martín *et al.*,
259 2014).

260 Transconjugants were selected by plating on Rambach agar supplemented with
261 tetracycline at 10µg/ml, which selected for CL32, and cefotaxime at 2µg/ml, which
262 selected for the incoming plasmid. Transconjugant colonies were sub-cultured and
263 tested by PCR using the CTX-M universal primers (Table 1) and by plasmid profiling
264 (Fig. 3) and the presence of a plasmid of ~100kb was confirmed in transconjugants of
265 CL32 (Table 2).

266

267 **Phenotypic impact of plasmid carriage upon *K. pneumoniae* B3791**

268 In growth competition studies, strain CL32 outcompeted *K. pneumoniae* strain B3791
269 (P=0.08), CL32-pIFM3791 (P<0.05), CL32-pIFM3804 (P<0.05) and CL32-pIFM3844

270 (P<0.05). A representative example of the data is shown in Fig. 4 and the summary of
271 the data in Table 3. For *K. pneumoniae* B3791 and its cured and complemented
272 derivatives no differences in association to IPEC-J2 monolayers were found. Crystal
273 violet biofilm assays performed at 25°C and 37°C found no differences when comparing
274 plasmid-free to plasmid-carrying strains.

275 In order to investigate subtler impacts in the metabolism of the strain caused by
276 plasmid carriage, Phenotype Microarrays (Biolog™) were performed on wild type *K.*
277 *pneumoniae* strain B3791, its IncII plasmid cured derivative CL32 and complemented
278 strain CL32-pIFM3791. There were four compounds for which one measurable
279 parameter of respiration for the plasmid free strain CL32 was significantly higher (P-
280 value <0.05) than B3791 and CL32-pIFM3791 (Table 4). These were rate of increase
281 (RateI) on L-sorbose as a carbon source and maximum value achieved (MaxV) on
282 putrescine, γ -Amino-N-Butyric and Ala-Gly dipeptide as nitrogen sources.

283 Using caproic acid, 4-hydroxy benzoic acid and putrescine as carbon sources
284 there were significant differences between CL32 and B3791 or between CL32 and
285 CL32-pIFM3791. For L-alanine, L-proline and L-threonine although CL32 was better
286 able to respire on these compounds than the other two strains the difference was only
287 significant when compared to plasmid-complemented strain CL32-pIFM3791. Finally,
288 for dipeptide Ala-Thr significant differences were found for two different measures of
289 growth, MaxV and AUC, although, the comparisons differed for each measure. Whilst
290 the AUC for CL32 was significantly different only from CL32-pIFM3791, for MaxV all
291 three comparisons revealed significant differences (Table 4).

292

293 **Effect of plasmid carriage on *Salmonella* 4,5,12:i:- strain S348/11**

294 Having demonstrated the phenotypic impact of pIFM3791 upon *K. pneumoniae*, the
295 question arose as to whether similar phenotypic impacts might occur in other Gram
296 negative bacteria. We had previously noted that *E. coli* and *Salmonella*
297 Bovismorbificans and 4,5,12:i:- from the same farm carried pIFM3791-like plasmids,
298 which however could not be cured due to problems with cross-resistance. For this
299 reason cefotaxime-sensitive *Salmonella* 4,5,12:i:- originating from the original farm
300 were screened by PFGE, plasmid profiling, susceptibility testing and CTX-M PCR. An
301 isolate designated S348/11 was identified which was identical to the *Salmonella*
302 4,5,12:i:- by these measures except for the lack of carriage of a pIFM3791-like plasmid.
303 Plasmid pIFM3791 was introduced by conjugation into S348/11 and the phenotype of
304 transconjugants was tested as described above. The presence of the plasmid did not
305 affect competitive growth of the strains, their association and invasion of monolayers of
306 mammalian cell line IPEC-J2, or their ability to form biofilm.

307

308 **Discussion**

309 PFGE and PCR tests confirmed curing plasmid pIFM27 successfully excluded IncII
310 CTX-M plasmids from *K. pneumoniae* B3791, and other unrelated strains with 100%
311 efficiency. We showed also that the use of the curing plasmid could be extended by
312 incorporation of alternative resistance markers demonstrating that this approach has
313 wide applications dependent upon the incompatibility and selectable marker genes
314 cloned. Here, limited selectable markers precluded use in other multiple antibiotic
315 resistant strains. However, this should no longer be a major obstacle due to the presence
316 of restriction sites flanking the resistance cassette allowing for easy exchange of
317 markers.

318 Using cured derivative CL32 for phenotypic comparisons carried the risk that
319 differences may be caused by the curing process hence complemented CL32 derivatives
320 were also used. Plasmid cured CL32 out-competed both wild type and plasmid
321 complemented strains, which themselves behaved in essentially the same manner
322 suggesting a fitness burden was imposed by carriage of the test plasmids. In contrast, a
323 recent study of an ST7 IncI1-CTX-M-1 plasmid isolated from broilers in the
324 Netherlands found that its carriage did not impose a burden on the growth of its
325 *Escherichia coli* host (Fischer *et al.*, 2014) although previous findings suggest plasmids
326 can slow down the growth of naïve hosts (Lee & Edlin, 1985; Zünd & Lebek, 1980). In
327 the case of pIFM3791 it may have been recently acquired by *K. pneumoniae* and thus,
328 co-evolution between plasmid and host, which is known to ameliorate growth
329 disadvantage (Bouma & Lenski, 1988), may have not taken place by the time of
330 isolation on the farm. Other reasons for the differences in behaviour could be caused by
331 the actual sequence of the Dutch plasmid, as it displayed a different pMLST sequence
332 type than that of pIFM3791 and its sequence is otherwise unknown.

333 We did not investigate alternative selection markers and this precluded the construction
334 of a *Salmonella* 4,5,12:i:- plasmid cured derivative. As such, we introduced pIFM3791,
335 pIFM3804 and pIFM3844 into strain *Salmonella* 4.5.12:i- S348/11 which was a plasmid
336 free strain from the same farm. Given the available data, S348/11 was highly similar to
337 the original strain harbouring a pIFM3791 like plasmid, but it cannot be ruled out that it
338 may have in the past harboured one such plasmid, and already be somewhat adapted to
339 its carriage. Conversely, highly related versions of the plasmid were originally found in
340 *E. coli* and *Salmonella* 4,5,12:i:- strains as well as *K. pneumoniae*. If the plasmid was
341 introduced by a *Salmonella* 4,5,12:i:- strain into a *K. pneumoniae* strain this could also
342 account for a degree of pre-existing plasmid adaption to S348/11 but not B3791. This is

343 supported by previous description of *in vitro* adaptation of a plasmid genome resulting
344 in the amelioration of the fitness burden imposed upon its host (Modi & Adams, 1991).

345 Another interesting finding was the ability of CL32 to respire more efficiently
346 than the other two strains on ten substrates: *K. pneumoniae* B3791 and CL32-pIFM3791
347 behaved similarly giving confidence that plasmid pIFM3791 did impact metabolism
348 although sequence analysis did not suggest any obvious gene candidates. Nevertheless
349 many genes of unknown function may contribute and future transcriptional and targeted
350 mutagenesis studies may resolve the mechanisms behind the phenotypes. Whether the
351 suppression of respiratory activity using L-sorbose as a carbon source and putrescine, γ -
352 amino-N-butyric acid and dipeptide Ala-Gly as nitrogen sources impacts
353 epidemiologically is worthy of consideration. Of importance is the identification of
354 specific metabolically-based burdens mediated by the plasmid on *K. pneumoniae* which
355 could be explained if expression of plasmid genes diverts resources away from the
356 transcription of metabolic pathways involved in the growth under nutrient limiting
357 conditions. Transcriptional interference mediated by integrated plasmids has been noted
358 before (Zagaglia *et al.*, 1991).

359 Collectively, these data show that the effect that plasmid pIFM3791 has on its host is
360 highly dependent on that host's make up. *Salmonella* 4,5,12:i:- strain 348/11 was better
361 able to carry the outbreak plasmids than the plasmid in *K. pneumoniae* strain B3791.
362 Given its similarity to plasmid bearing isolates it is possible S348/11 is a naturally cured
363 strain and adapted to the burdens imposed by the plasmid. Additionally, the experiments
364 here also show that whether an effect is detectable or not will depend on the exact
365 aspect of fitness that is being measured. The implication of these findings for the
366 reversal of antimicrobial resistance is that even if there is a fitness cost for a certain
367 strain of pathogenic bacteria, as long as there are others in its environment for which

368 such cost does not exist, and given the mobility of conjugative plasmids, once the
369 selection pressure is imposed by means of the antibiotic, the plasmid can spread again.
370 For this reason, it would have been interesting to have carried out the experiments with
371 *E. coli* strains isolated from the farm. *E. coli* are often found to be harmless
372 commensals, and if it was found that plasmid carriage is either beneficial or neutral for
373 them, this could further lend weight to the idea that plasmids are maintained by certain
374 strains and that are then taken up by other strains in times of selective pressure.

375

376 **Acknowledgements**

377 We would like to thank staff and students at the APHA Department of Bacteriology
378 PhD students for their support. Part of the data discussed in this article has been
379 presented at the PhD Student Oral presentation section of the 2012 BSAC ARM
380 Workshop for Researchers in Birmingham.

381 **Funding**

382 This study was funded by 'Seedcorn' funds through the Department of Bacteriology at
383 APHA in support of IFM's PhD project.

384 **Transparency declarations**

385 None to declare.

386

387

388 **References**

- 389 **Batchelor, M., Hopkins, K., Threlfall, E. J., Clifton-Hadley, F. A., Stallwood, A. D., Davies, R. H.**
390 **& Liebana, E. (2005).** bla(CTX-M) genes in clinical Salmonella isolates recovered from
391 humans in England and Wales from 1992 to 2003. *Antimicrob Agents Chemother* **49**,
392 1319–22.
- 393 **De Been, M., Lanza, V. F., de Toro, M., Scharringa, J., Dohmen, W., Du, Y., Hu, J., Lei, Y., Li, N.**
394 **& other authors. (2014).** Dissemination of cephalosporin resistance genes between
395 *Escherichia coli* strains from farm animals and humans by specific plasmid lineages. *PLoS*
396 *Genet* **10**, e1004776.
- 397 **Bouma, J. E. & Lenski, R. E. (1988).** Evolution of a bacteria/plasmid association. *Nature* **335**,
398 351–2.
- 399 **Couturier, M., Bex, F., Bergquist, P. L. & Maas, W. K. (1988).** Identification and classification of
400 bacterial plasmids. *Microbiol Rev* **52**, 375–95.
- 401 **El-Sayed, A. K., Hothersall, J. & Thomas, C. M. (2001).** Quorum-sensing-dependent regulation
402 of biosynthesis of the polyketide antibiotic mupirocin in *Pseudomonas fluorescens*
403 NCIMB 10586. *Microbiology* **147**, 2127–2139.
- 404 **Enne, V. I., Bennett, P. M., Livermore, D. M. & Hall, L. M. C. (2004).** Enhancement of host
405 fitness by the sul2-coding plasmid p9123 in the absence of selective pressure. *J*
406 *Antimicrob Chemother* **53**, 958–63.
- 407 **Favre-Bonte, S., Joly, B. & Forestier, C. (1999).** Consequences of reduction of *Klebsiella*
408 *pneumoniae* capsule expression on interactions of this bacterium with epithelial cells.
409 *Infect Immun* **67**, 554–61.
- 410 **Ferguson, L. R. & Denny, W. A. (2007).** Genotoxicity of non-covalent interactions: DNA
411 intercalators. *Mutat Res* **623**, 14–23.
- 412 **Fischer, E. A., Dierikx, C. M., van Essen-Zandbergen, A., van Roermund, H. J., Mevius, D. J.,**
413 **Stegeman, A. & Klinkenberg, D. (2014).** The IncI1 plasmid carrying the blaCTX-M-1 gene
414 persists in in vitro culture of a *Escherichia coli* strain from broilers. *BMC Microbiol* **14**, 77.
- 415 **Freire Martín, I., Abuoun, M., Reichel, R., La Ragione, R. M. & Woodward, M. J. (2014).**
416 Sequence analysis of a CTX-M-1 IncI1 plasmid found in *Salmonella* 4,5,12:i:-, *Escherichia*
417 *coli* and *Klebsiella pneumoniae* on a UK pig farm. *J Antimicrob Chemother* 2098–2101.
- 418 **Gerner-Smidt, P., Hise, K., Kincaid, J., Hunter, S., Rolando, S., Hyytiä-Trees, E., Ribot, E. M. &**
419 **Swaminathan, B. (2006).** PulseNet USA: a five-year update. *Foodborne Pathog Dis* **3**, 9–
420 19. Mary Ann Liebert, Inc. 2 Madison Avenue Larchmont, NY 10538 USA.
- 421 **Gniadkowski, M. (2001).** Evolution and epidemiology of extended-spectrum beta-lactamases
422 (ESBLs) and ESBL-producing microorganisms. *Clin Microbiol Infect* **7**, 597–608.
- 423 **Hale, L., Lazos, O., Haines, A. & Thomas, C. (2010).** An efficient stress-free strategy to displace
424 stable bacterial plasmids. *Biotechniques* **48**, 223–8.

- 425 **Horton, R. A., Randall, L. P., Snary, E. L., Cockrem, H., Lotz, S., Wearing, H., Duncan, D., Rabie,**
426 **A., McLaren, I. & other authors. (2011).** Fecal carriage and shedding density of CTX-M
427 extended-spectrum {beta}-lactamase-producing escherichia coli in cattle, chickens, and
428 pigs: implications for environmental contamination and food production. *Appl Environ*
429 *Microbiol* **77**, 3715–9.
- 430 **Kado, C. I. & Liu, S. T. (1981).** Rapid procedure for detection and isolation of large and small
431 plasmids. *J Bacteriol* **145**, 1365–73.
- 432 **Lee, S. W. & Edlin, G. (1985).** Expression of tetracycline resistance in pBR322 derivatives
433 reduces the reproductive fitness of plasmid-containing Escherichia coli. *Gene* **39**, 173–80.
- 434 **Lenski, R. E., Simpson, S. C. & Nguyen, T. T. (1994).** Genetic analysis of a plasmid-encoded,
435 host genotype-specific enhancement of bacterial fitness. *J Bacteriol* **176**, 3140–7.
- 436 **Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G.,**
437 **Ayala, J., Coque, T. M., Kern-Zdanowicz, I. & other authors. (2007).** CTX-M: changing the
438 face of ESBLs in Europe. *J Antimicrob Chemother* **59**, 165–74.
- 439 **Kahm, M., Hasenbrink, G., Lichtenberg-Fraté, H., Ludwig, J. & Kschischo, M. (2010).** grofit:
440 fitting biological growth curves with R. *J Stat Softw* **33**, 1–21.
- 441 **Modi, R. I. & Adams, J. (1991).** Coevolution in Bacterial-Plasmid Populations. *Evolution (N Y)*
442 **45**, 656–667. Society for the Study of Evolution.
- 443 **Pitout, J. D. D., Gregson, D. B., Church, D. L., Elsayed, S. & Laupland, K. B. (2005).** Community-
444 wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli
445 strains in the Calgary health region. *J Clin Microbiol* **43**, 2844–9.
- 446 **Praszkier, J. & Pittard, A. J. (2005).** Control of replication in I-complex plasmids. *Plasmid* **53**,
447 97–112.
- 448 **Randall, L., Wu, G., Phillips, N., Coldham, N., Mevius, D. & Teale, C. (2012).** Virulence genes in
449 bla(CTX-M) Escherichia coli isolates from chickens and humans. *Res Vet Sci* **93**, 23–7.
- 450 **Searle, L. E. J., Best, a., Nunez, a., Salguero, F. J., Johnson, L., Weyer, U., Dugdale, a. H.,**
451 **Cooley, W. a., Carter, B. & other authors. (2009).** A mixture containing
452 galactooligosaccharide, produced by the enzymic activity of Bifidobacterium bifidum,
453 reduces Salmonella enterica serovar Typhimurium infection in mice. *J Med Microbiol* **58**,
454 37–48.
- 455 **Shaw, K. J., Rather, P. N., Hare, R. S. & Miller, G. H. (1993).** Molecular Genetics of
456 Aminoglycoside Resistance Genes and Familial Relationships of the Aminoglycoside-
457 Modifying Enzymes **57**.
- 458 **Tatsuno, I., Horie, M., Abe, H., Miki, T., Makino, K., Shinagawa, H., Taguchi, H., Kamiya, S.,**
459 **Hayashi, T. & Sasakawa, C. (2001).** toxB gene on pO157 of enterohemorrhagic
460 Escherichia coli O157:H7 is required for full epithelial cell adherence phenotype. *Infect*
461 *Immun* **69**, 6660–9.

- 462 **Woodward, M. J., Sojka, M., Sprigings, K. A. & Humphrey, T. J. (2000).** The role of SEF14 and
463 SEF17 fimbriae in the adherence of *Salmonella enterica* serotype Enteritidis to inanimate
464 surfaces. *J Med Microbiol* **49**, 481–7.
- 465 **Zagaglia, C., Casalino, M., Colonna, B., Conti, C., Calconi, A. & Nicoletti, M. (1991).** Virulence
466 plasmids of enteroinvasive *Escherichia coli* and *Shigella flexneri* integrate into a specific
467 site on the host chromosome: integration greatly reduces expression of plasmid-carried
468 virulence genes. *Infect Immun* **59**, 792–9.
- 469 **Zünd, P. & Lebek, G. (1980).** Generation time-prolonging R plasmids: correlation between
470 increases in the generation time of *Escherichia coli* caused by R plasmids and their
471 molecular size. *Plasmid* **3**, 65–9.
- 472

473 **Legends**

474 **Figure 1:** Genetic map of IncI1 curing vector pIFM27. The features coloured in black
475 represent genetic structures already present in vector pIFM26 whilst the features
476 coloured in grey are those added in this study.

477

478 **Figure 2:** Plasmid profiling DNA gel electrophoresis of B3791, its pIFM27
479 transformant derivatives CL28 and, pIFM27 free derivatives CL31 and CL32. 20R764
480 is a reference plasmid free *E. coli* for identification of the chromosomal DNA band
481 plasmids of B3791 and its derivatives. The band of approximately 8kb in CL28
482 corresponds to the introduced pIFM27 curing vector. In lanes CL28 to CL32 the native
483 CTX-M IncI1 p3791 has been lost.

484

485 **Figure 3: a) Plasmid profiling of S348/11 and its outbreak plasmid harbouring**
486 **transconjugants.** Plasmid profiling DNA gel electrophoresis of strain S348/11 and its
487 outbreak plasmid carrying derivatives. 20R764 is a reference plasmid free *E. coli* for
488 identification of the chromosomal DNA band. 39R861 is a reference strain carrying four
489 plasmids of known sizes as labelled. Strain S348/11 carries no plasmids as shown in this
490 gel, its transconjugants have acquired a plasmid of around 100kb, circled blue. **b)**

491 **Plasmid profiling of CL32 transconjugants complemented with the outbreak**
492 **plasmids.** Plasmid profiling DNA gel electrophoresis of strain CL32 transconjugants.
493 T91-3 plasmid DNA has been included as a reference of the outbreak plasmid size
494 (circled red). 20R764 is a reference plasmid free *E. coli* for identification of the
495 chromosomal DNA band. 39R861 is a reference strain carrying four plasmids of known
496 sizes as labelled. All transconjugants have acquired a plasmid of around 100kb, circled
497 blue.

498

499 **Figure 4:** Representative example of a competition experiment of strain CL32 vs.
500 B3791. The \log_e of the ratio of plasmid bearing over plasmid free organisms on each
501 day has been plotted. The negative slope of the line of best fit denotes that B3791 is
502 being outcompeted by CL32.

503

504 **Table 1: Primers used in this study**

Primer	Sequence
RNAFW	TCTAGAATATCTCGAGTGCACAGGGTTGAATCTC
RNARV	GGATCCTGTTCCGGAAGCCATAAA
M13FW	GTAAAACGACGGCCAG
M13RV	CAGGAAACAGCTATGAC
PRE-MCS	GCGATTAAGTTGGGTAACG
aac6'IbFW	GAATTCATGAGCAACGCAAAAACA
aac6'IbRV	GAATTCTTAGGCATCACTGCGTGT

505

506 **Table 2: List of plasmid complemented strains of CL32 and S348/11 as well as**
 507 **plasmid donor lab strains T91a, T04a and T44a.**

508

Strain	Parent	Species	CTX-plasmid
T91a	NEB10-beta	<i>E. coli</i>	pIFM3791
T04a	NEB10-beta	<i>E. coli</i>	pIFM3804
T44a	NEB10-beta	<i>E. coli</i>	pIFM3844
CL32-pIFM3791	CL32	<i>K. pneumoniae</i>	pIFM3791
CL32-pIFM3804	CL32	<i>K. pneumoniae</i>	pIFM3804
CL32-pIFM3844	CL32	<i>K. pneumoniae</i>	pIFM3844
S348/11	NA	<i>S. enterica</i>	NA
S348/11-pIFM3791	S348/11	<i>S. enterica</i>	pIFM3791
S348/11-pIFM3804	S348/11	<i>S. enterica</i>	pIFM3804
S348/11-pIFM3844	S348/11	<i>S. enterica</i>	pIFM3844

509

510 **Table 3: Effect of plasmid carriage on the competitive fitness of strains B3791 and**
 511 **S348/11**

Plasmid-less	Plasmid-carrying	Selection rate	P-value
	B3791	-0.29	0.08
CL32	CL32-pIFM3791	-0.19	0.009
	CL32-pIFM3804	-0.22	0.011
	CL32-pIFM3844	-0.27	0.006
	S348/11-pIFM3804	-0.01	0.954
S348/11	S348/11-pIFM3844	0.01	0.957

512

513 Competition experiment results (Selection Rate) and their statistical significance as
 514 assessed by a two tailed T test (P value). Highlighted in grey are those results
 515 considered to be significantly different from no selection (P<0.05).


516 **Table 4: Effect of plasmid carriage on the metabolism of *K. pneumoniae* B3791 as assessed by Phenotype Microarray Biolog.**


Compound (Plate, Well)	Feature	Strain order	<i>P</i> values of comparisons by Tukey's HSD		
			CL32 vs. B3791	CL32-pIFM3791 vs. B3791	CL32::pIFM3791 vs. CL32
L-Sorbose (PM2, D04)	RateI	CL32 > CL32-pIFM3791 > B3791	0.009	0.974	0.012
Caproic acid (PM2, E02)	MaxV	CL32 > CL32-pIFM3791 > B3791	0.013	0.145	0.194
	AUC	CL32 > CL32-pIFM3791 > B3791	0.031	0.430	0.164
4-Hydroxy Benzoic Acid (PM2, E07)	RateI	CL32 > B3791 > CL32-pIFM3791	0.159	0.174	0.013
	RateI	CL32 > B3791 > CL32-pIFM3791	0.072	0.904	0.042
Putrescine (PM2, H08)	MaxV	CL32 > CL32-pIFM3791 > B3791	0.033	0.736	0.085
	AUC	CL32 > CL32-pIFM3791 > B3791	0.029	0.679	0.082
L-Alanine (PM3, A07)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.165	0.472	0.035
L-Proline (PM3, B09)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.104	0.566	0.028
L-Threonine (PM3, B11)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.054	0.464	0.012
	AUC	CL32 > B3791 > CL32-pIFM3791	0.098	0.526	0.024
Putrescine (PM3, D11)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.029	0.456	0.007
γ -Amino-NButyric Acid (PM03, G08)	MaxV	CL32 > CL32-pIFM3791 > B3791	0.026	0.991	0.030
Ala-Gly (PM3, H04)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.026	0.768	0.012
Ala-Thr (PM3, H07)	MaxV	CL32 > B3791 > CL32-pIFM3791	0.025	0.033	0.001
	AUC	CL32 > B3791 > CL32-pIFM3791	0.236	0.238	0.024


517


518 Listed are the compounds for which significant differences in their respiration were found for at least one of the features tested. Results that
519 reach statistical significance have been highlighted in grey.

520 * MaxV = maximum value achieved, RateI = fastest rate of increase, AUC = area under the curve.









1 SUPPLEMENTARY MATERIAL

2 All molecular biological methods including DNA extraction, measurement of DNA purity
3 and concentration, PCR, restriction digestion of DNA, agarose gel electrophoresis, ligation,
4 transformation, electroporation and selection followed standard procedures(Sambrook, J., E.
5 F. Fritsch, n.d.) and manufacturer's conditions for use of reagents. Sequencing reactions were
6 carried out by the AHVLA Central Sequencing Unit.

7

8 Construction of IncI1 curing vector plasmid pIFM27 *RNAI1 aac6-Ib*

9 Primers were designed to amplify the *RNAI* gene along with its native promoter with
10 tails on both forward (RNAIFW), and reverse (RNARV) primers (Table 1) that introduced
11 *XbaI* and *XhoI* sites to the 5' and a *BamHI* site to the 3' of the *RNAI* gene. Using plasmid
12 pIFM3804 DNA as template, the PCR generated a product of the correct size that blunt end
13 cloned into pCR-Blunt. Plasmid DNA extracted from four transformants was digested using
14 *XbaI* and *BamHI* which confirmed the presence of an insert of the predicted size and
15 sequencing with insert flanking primers (M13FW and M13RV) showed complete integrity of
16 *RNAI*.

17 Plasmid DNA from one transformant was digested with *XbaI* and *BamHI* and the
18 *RNAI* insert was gel purified and ligated with vector pIFM26, previously digested with *XbaI*
19 and *BamHI*. pIFM26 was identical to previously described pAKE604,(El-Sayed *et al.*, 2001)
20 with a minor modification to invert its multiple cloning site. The ligated DNA was used to
21 transform *E. coli* DH5 α with ampicillin selection (100mg/L). To verify the constructs,
22 plasmid DNA extracted from three well isolated transformants was digested with *BglIII* and
23 *XhoI* to confirm the predicted total and fragment size of the plasmid and was used as target
24 for PCR and sequencing using *RNAI*-FW and Pre-MCS primers (Table 1). One transformant
25 designated CL19 was retained for further work.

26 As the outbreak strains were already resistant to kanamycin and ampicillin, the
 27 markers present on pIFM26, an alternative resistance marker, amikacin, was chosen for
 28 inclusion in the curing vector. The amikacin resistance gene *aac6'-Ib* was amplified using
 29 forward and reverse primers, *aac6'-IbFW* and *aac6'-IbRW* that included *EcoRI* tails (Table
 30 1), using as target the wild type plasmid isolated by C. Boinet as part of her PhD studies
 31 (Phenotypic and genotypic analysis of blaCTX-M encoding plasmids isolated from bovine *E.*
 32 *coli* samples in the United Kingdom: Royal Holloway, University of London). The *aac6'-Ib*
 33 gene product was cloned into pCR-Blunt in *E. coli* NEB5 α with selection for kanamycin
 34 (50mg/L). Plasmid DNA extracted from five transformants was used in PCR with primers
 35 flanking the insertion site (M13FW and M13RV) to confirm presence of the insert (expected
 36 ~800bp band) and the product integrity was confirmed by sequence analysis. One
 37 transformant designated CL25 was retained for further work.

38 Plasmid DNA extracted from CL25 was digested with *EcoRI* and the *aac6'-Ib*
 39 fragment was cloned into the *EcoRI* site of pIFM19 DNA in *E. coli* NEB5 α with selection for
 40 transformants resistant to ampicillin (100mg/L). Only one colony was found and PCR
 41 analysis using primer pairs *aac6'-IbFW* and Pre-MCS and *aac6'-IbRV* and Pre-MCS
 42 confirmed the correct orientation of the insert with respect to the LacZ promoter to drive its
 43 expression. The resulting strain was named CL27 and its plasmid pIFM27 (Figure 1).

44 **Table S1: Sequence differences in outbreak plasmids pIFM3791, pIFM3804 and**
 45 **pIFM3844**

Position in pIFM3804	Sequence			Gene	Effect
	pIFM3791	pIFM3804	pIFM3844		
6148	G	G	A	<i>ISCR2</i>	serine to phenylalanine in pIFM3844
10994	CG	-G	-	outside coding region	NA
19884	G	-	G	<i>ybaA</i>	frameshift (in pIFM3791 and pIFM3844)
24941	A	-	A	hypothetical protein	frameshift (in pIFM3791 and pIFM3844)
56570	A	-	A	hypothetical protein	frameshift (in pIFM3791 and pIFM3844)
57253	T	-	T	outside coding region	NA
58328	T	-	T	<i>exc</i>	frameshift (in pIFM3791 and pIFM3844)

46 **References**

- 47 **El-Sayed, A. K., Hothersall, J. & Thomas, C. M. (2001).** Quorum-sensing-dependent
48 regulation of biosynthesis of the polyketide antibiotic mupirocin in *Pseudomonas*
49 *fluorescens* NCIMB 10586. *Microbiology* **147**, 2127–2139.
- 50 **Sambrook, J., E. F. Fritsch, and T. M. (n.d.).** *Molecular cloning: a laboratory manual, 2nd*
51 *ed.* Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press.